glp-1 receptor agonists in idiopathic intracranial hypertension Treatment with is associated with significant weight loss and favorable headache outcomes | The Journal of Headache and Pain Recurrent Idiopathic Intracranial Hypertension–Related Papilledema
Description
Diabetes Obesity and Metabolism
The beneficial actions based on activation of the entero-insular axis are complex and multitargeted, involving the gut, brain, pancreas, and liver
Abstract Background Obesity has emerged as a pressing global health challenge, and therapies based on glucagon-like Peptide 1 receptor agonists (GLP-1RAs) have transformed its management
The cardiovascular benefits, including reductions in MACE and stroke, also accumulate over time, with the most substantial gains observed within the first 24 to 36 months of treatment [124, 125]
